IBO · Impact Biomedical Inc.
$0.48
+0.03 (+6.83%)
At close · Aug 21
Going-concern doubt
— flagged Aug 7, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As reflected in the accompanying financial statements the Company has incurred operating losses as well as negative cash flows from operating activities over the past two years. These factors raise substantial doubt about the Company's ability to continue as a going concern within one year of the date that the financial statements are issued.”View the 10-Q filed Aug 7, 2026
Market Cap
$51.75M
Shares
107.82M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.48
Open$0.44
Day$0.44–0.48
52W close$0.40–0.78
Avg vol 30d31K
Short int555K · 0.5% float · 27.1d
Short vol34%
DataSep 2024–Aug 2026
Filing10-Q · Aug 7
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 7, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.1 · calm
Equity put/call 0.51
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−7%
below
Price vs 50-day avg
+3%
above
RSI (14)
57
neutral
MACD trend
Positive
52-week position
21%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+9%
trailing
6-month return
+20%
trailing
YTD return
−5%
this year
Relative strength
+8%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+10% holders QoQ · +3 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.51% of float · ▼ -0.4% MoM · 27.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
23 holders — mid 2-yr range
Squeeze score
50
elevated · 0–100
Fundamentals
Revenue growth
−36%
Y/Y
EPS growth
+83%
Y/Y
Balance sheet
$12.1M
net debt
Quant / Vol
risk profile
Volatility
120%
annualized · 1-yr
Max drawdown
−45%
past year
ATR
6.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−7%
Bearish
Price vs 50-day avg
+3%
Bullish
RSI (14)
57
Neutral
MACD trend
Positive
Bullish
52-week position
21%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+10% holders QoQ · +3 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.51% of float · ▼ -0.4% MoM · 27.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
23 holders — mid 2-yr range
Price context
position in its 52-week range
Range low $0
Now $0 · 21%
Range high $1
vs 200-day avg -7%
vs 50-day avg +3%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IBO
this stock
Impact Biomedical Inc.
|
$51.75M | -5.0% | — | — | 0.5% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.91B | +20.9% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$85.87B | +8.1% | +20.8% | 20.7 | 3.3% |
|
ARGX
Argenx SE
|
$64.66B | +23.6% | — | — | 2.1% |
|
CSLLY
Csl Ltd
|
$57.97B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IBO | +4.6% | +9.1% | +19.7% | +11.6% | -5.0% |
| SPY | -1.4% | +3.6% | +11.6% | +2.5% | +12.3% |
| vs SPY | +6.0% | +5.5% | +8.1% | +9.1% | -17.2% |